Chronic fatigue syndrome and the immune system: Where are we now?
Mensah, Fane Kojo Fosu, Bansal, Amolak Singh, Ford, Brian et al. · Neurophysiologie clinique = Clinical neurophysiology · 2017 · DOI
Quick Summary
ME/CFS is a complex illness that causes exhaustion, headaches, and thinking problems, and gets worse with activity. Researchers have suspected for years that the immune system plays a role in ME/CFS, but studies have produced confusing and sometimes contradictory results. This review examines what we currently know about immune system changes in ME/CFS and discusses promising new research directions, including the possibility that certain immune-targeting treatments might help patients improve.
Why It Matters
Understanding the immune mechanisms in ME/CFS is critical because it may lead to targeted treatments—the review notes that B cell depletion therapy shows clinical promise, offering hope for patients with limited current treatment options. This systematic review synthesizes existing immunological evidence to guide future research directions and help explain why ME/CFS symptoms often begin after infections.
Observed Findings
Natural killer cell dysfunction has been reported by multiple research groups, particularly in patients with post-infection disease onset
Cytokine data across different studies have shown inconsistency and lack of consensus patterns
Larger patient cohorts analyzed with more sophisticated methodologies have recently produced more robust and reproducible immune data
B cell depletion therapies have shown potential to produce clinical improvement in some patients
Multiple components of the immune system appear to be altered in ME/CFS, with significant variation between individuals
Inferred Conclusions
The immune system likely plays a significant role in ME/CFS pathogenesis, possibly triggered or initiated by viral infections
Increased research investment using standardized, sophisticated methodologies across large cohorts is needed to clarify consistent immune abnormalities
B cell depletion represents a promising therapeutic avenue that warrants further investigation
Understanding ME/CFS requires repeated analysis across different patient populations to account for disease heterogeneity
Remaining Questions
What causes the inconsistency in cytokine findings between different studies, and can standardized methods resolve this?
What This Study Does Not Prove
This review does not prove that immune dysfunction is the sole cause of ME/CFS, nor does it establish causation between specific immune markers and disease symptoms. The authors acknowledge significant inconsistencies between studies, meaning no single immune abnormality has been definitively confirmed as universal to all ME/CFS patients. It does not compare the effectiveness of B cell depletion therapy head-to-head with other treatments.